Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 35% Improvement Relative Risk Guglielmetti et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 218 patients in Italy Lower mortality with HCQ (not stat. sig., p=0.22) Guglielmetti et al., J. Infection and Public Hea.., doi:10.1016/j.jiph.2020.11.012 Favors HCQ Favors control
Severe COVID-19 pneumonia in Piacenza, Italy – a cohort study of the first pandemic wave
Guglielmetti et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2020.11.012
Guglielmetti et al., Severe COVID-19 pneumonia in Piacenza, Italy – a cohort study of the first pandemic wave, Journal of Infection and Public Health, doi:10.1016/j.jiph.2020.11.012
Dec 2020   Source   PDF  
  All Studies   Meta
Retrospective 218 hospitalized patients in Italy showing non-statistically significant 35% lower mortality with HCQ, hazard ratio aHR 0.65 [0.33–1.30].
risk of death, 35.0% lower, RR 0.65, p = 0.22, treatment 181, control 37, adjusted per study, multivariable Cox.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Guglielmetti et al., 9 Dec 2020, retrospective, Italy, peer-reviewed, 16 authors, average treatment delay 8.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Journal of Infection and Public Health 14 (2021) 263–270 Contents lists available at ScienceDirect Journal of Infection and Public Health journal homepage: Severe COVID-19 pneumonia in Piacenza, Italy — A cohort study of the first pandemic wave Lorenzo Guglielmetti a,b,c,∗ , Irina Kontsevaya d,e,f , Maria C. Leoni c , Patrizia Ferrante c,g , Elisa Fronti c , Laura Gerna c , Caterina Valdatta c , Alessandra Donisi h , Alberto Faggi c , Franco Paolillo c , Giovanna Ratti c , Alessandro Ruggieri c , Marta Scotti c , Daria Sacchini c , Gloria Taliani c,i,j,1 , Mauro Codeluppi c,1 , For the COVID-Piacenza Group2 a Sorbonne Université, INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, Cimi-Paris, équipe 13, Paris, France APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France c Infectious Diseases Unit, Piacenza Hospital, Piacenza, Italy d Research Center Borstel, Borstel, Germany e German Center for Infection Research, Hamburg-Lübeck-Borstel-Riems, Borstel, Germany f International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany g Institute for Cross-Disciplinary Physics and Complex Systems IFISC (UIB-CSIC), Campus Universitat Illes Balears, E-07122 Palma de Mallorca, Spain h Migration Health Unit, Primary Health Care Department, “Guglielmo da Saliceto” Hospital, Piacenza, Italy i Infectious and Tropical Disease Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy j Anti-COVID Task Force of the Italian Civil Protection b a r t i c l e i n f o Article history: Received 11 August 2020 Received in revised form 13 November 2020 Accepted 18 November 2020 Keywords: SARS-CoV-2 Coronavirus Viral pneumonia Acute respiratory distress syndrome Mortality a b s t r a c t Background: Piacenza is the closest city to the first coronavirus disease 2019 (COVID-19) cluster in Italy and has the highest national COVID-19 death rates per population. The objective of this study is to present characteristics and outcomes of patients admitted to medical departments of the Hospital of Piacenza during the first wave of the epidemic. Methods: A total of 218 patients with confirmed or suspect COVID-19 and severe pneumonia were included from February 21st to May 15th, 2020. Routinely-collected clinical and laboratory data were retrospectively retrieved from electronic medical files. A Cox proportional-hazards model was fit to assess the association of treatment and other variables with death. Results: Median age of patients was 68 years; 150 patients (69%) had comorbidities, mainly hypertension (107, 49%). Overall, 185 (85%) patients had acute respiratory distress syndrome (ARDS) on admission, including 103 (47%) with moderate or severe ARDS. Chest computed tomography scan showed bilateral disease in 201 (98%) and extensive lung involvement in 79 (50%) patients. Most patients received antiviral treatment (187, 86%) and corticosteroids (134, 61%). All patients received respiratory support and 64 (29%) were admitted to intensive care unit. As of June 30th, 100 patients (46%) died, 109 patients (50%) were discharged, and 9 patients (4%) were still hospitalized. In multivariable Cox analysis, age above 65 years, having more than one comorbidity, severe ARDS, low platelet counts, and high LDH levels at..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop